Heart protection study for people with heart disease and overweight
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 45 years or older.
- You have a body mass index (BMI) of 27 or higher, which means you are overweight or have obesity.
- You have a history of a heart attack, a stroke, or blocked arteries in your legs (peripheral artery disease).
- You have not had a heart attack, stroke, or major heart procedure in the past 60 days.
- You do not have type 1 diabetes, and if you have type 2 diabetes, your blood sugar control is moderate (A1C not above 10%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This study is testing whether a new medicine, called Maridebart Cafraglutide, can help people with obstructive sleep apnea who are already using a CPAP machine. The medicine may help with weight loss and potentially improve sleep apnea. Participants will either receive the medicine or a placebo (an inactive substance), and the study lasts for several months.
This study tests if a weight management program helps people with a new type of irregular heartbeat (atrial fibrillation) and obesity. It aims to see if losing weight can improve heart rhythm and reduce the need for further treatment.
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
Hear when a new Atherosclerotic Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.